• Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs biospace
    May 05, 2019
    The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.
  • Single-cell sequencer Mission Bio adds 3 execs fiercebiotech
    April 28, 2019
    Single-cell genomics developer Mission Bio has made three new hires to build out its executive team, following a $30 million series B round late last year and a new deal to provide sequencing services to LabCorp and its Covance drug development business.
PharmaSources Customer Service